

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-25. (canceled).

26. A method of inhibiting tumor growth in a mammal comprising administering to a liver cell of said mammal a compound which inhibits HAAH hydroxylation of a NOTCH polypeptide of an aspartic acid or asparagine residue of an EGF-like repeat sequence of a NOTCH polypeptide, said repeat sequence comprising the amino acid sequence of SEQ ID NO:4, by an endogenous human aspartyl (asparaginy) beta-hydroxylase (HAAH) polypeptide, wherein said cell overexpresses said HAAH polypeptide and wherein said HAAH polypeptide comprises the amino acid sequence of SEQ ID NO:2.

B4
27. (canceled) The method of claim 26, wherein said compound inhibits hydroxylation of an EGF-like repeat sequence in a NOTCH polypeptide.

28-38. (canceled)

39. (canceled) The method of claim 27, wherein said sequence comprises SEQ ID NO:4.

40. (canceled) The method of claim 26, wherein said tumor is selected from the group consisting of colon cancer, breast cancer, pancreatic cancer, liver cancer, and cancer of the bile ducts.

41. (withdrawn) The method of claim 26, wherein said tumor is a cancer of the central nervous system.

42. (originally filed) The method of claim 26, wherein said tumor is a hepatocellular carcinoma.

43. (withdrawn) The method of claim 26, wherein said tumor is a cholangiocarcinoma.

44. (withdrawn) The method of claim 26, wherein said tumor is a glioblastoma.

45. (withdrawn) The method of claim 26, wherein said tumor is a neuroblastoma.

B4 46. (newly added) The method of claim 26, wherein said mutation is a substitution which changes a ferrous iron binding site from histidine to a non-iron-binding amino acid.

47. (newly added) A method of inhibiting tumor growth in a mammal comprising administering to said mammal a polypeptide comprising a mutation at position 671, 675, 679, or 690 of SEQ ID NO:2, wherein said polypeptide inhibits hydroxylation of an aspartic acid or asparagine residue of an EGF-like repeat sequence comprising the amino acid sequence of SEQ ID NO:4 by an endogenous HAAH polypeptide in a cell that overexpresses said HAAH polypeptide, wherein said HAAH polypeptide comprises the amino acid sequence of SEQ ID NO:2.
